Evidence map›Paper›PMID 35286719›Full record

ArticleBritish journal of haematology2022

Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?

Mouhamed Yazan Abou-Ismail, Raphael Fraser, Mariam Allbee-Johnson, Leland Metheny, Gayathri Ravi, Kwang Woo Ahn, Neel S Bhatt, Hillard M Lazarus, Marcos de Lima, Najla El Jurdy and 10 more

Open access · greenAbstract read
In one paragraph

Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 2 countries.

Mouhamed Yazan Abou-IsmailDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Raphael FraserCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Mariam Allbee-JohnsonCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Leland MethenyAdult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Gayathri RaviDivision of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kwang Woo AhnCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Neel S BhattClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Marcos de LimaThe James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.
Najla El JurdyThe Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-9268-9655
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, WI, USA.
Amer M BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0002-2621-7924
Sherif M BadawyDivision of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.ORCID 0000-0002-4739-265X
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Marcelo C PasquiniCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0003-1579-2293
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Mohamed L SorrorClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Edward A StadtmauerUniversity of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
Saurabh ChhabraCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0001-9117-8696
Medical College of Wisconsin · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAMoffitt Cancer Center · USNorthwestern University · USSt. Jude Children's Research Hospital · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity Hospitals of Cleveland · USUniversity Hospitals Seidman Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of Miami Hospital · USUniversity of Minnesota · USUniversity of Pennsylvania · USUniversity of Utah · USUniversity of Washington Medical Center · USUniversity of Wisconsin–Madison · USVanderbilt University Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

It is not known whether obesity has a differential effect on allogeneic haematopoietic cell transplantation outcomes with alternative donor types. We report the results of a retrospective registry study examining the effect of obesity [body mass index (BMI) > 30] on outcomes with alternative donors (haploidentical related donor with two or more mismatches and receiving post-transplant cyclophosphamide [haplo] and cord blood (CBU)] versus matched unrelated donor (MUD). Adult patients receiving haematopoietic cell transplantation for haematologic malignancy (2013-2017) (N = 16 182) using MUD (n = 11 801), haplo (n = 2894) and CBU (n = 1487) were included. The primary outcome was non-relapse mortality (NRM). The analysis demonstrated a significant, non-linear interaction between pretransplant BMI and the three donor groups for NRM: NRM risk was significantly higher with CBU compared to haplo at BMI 25-30 [hazard ratio (HR) 1.66-1.71, p < 0.05] and MUD transplants at a BMI of 25-45 (HR, 1.61-3.47, p < 0.05). The results demonstrated that NRM and survival outcomes are worse in overweight and obese transplant recipients (BMI ≥ 25) with one alternative donor type over MUD, although obesity does not appear to confer a uniform differential mortality risk with one donor type over the other. BMI may serve as a criterion for selecting a donor among the three (MUD, haplo and CBU) options, if matched sibling donor is not available.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultBody Mass IndexDonor SelectionHumansNeoplasm Recurrence, LocalObesityRetrospective StudiesUnrelated Donorsallogeneic cell transplantalternative donor typescord blood unitshaploidenticalnon-relapse mortalityobesity

Identifiers

PMID35286719
PMCPMC9675037
OpenAlexW4220701563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.